Arrhythmogenic cardiomyopathy

Last updated
Arrhythmogenic cardiomyopathy
Other namesArrhythmogenic right ventricular cardiomyopathy (ARVC), arrhythmogenic right ventricular dysplasia (ARVD)
Arrhythmogenic right ventricular cardiomyopathy - histology.jpg
Typical micro-histologic features of ARVC/D. Ongoing myocyte death (upper) with early fibrosis and adipocyte infiltration (lower).
Specialty Cardiology

Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease. [1]

Contents

ACM is caused by genetic defects of parts of the cardiac muscle known as desmosomes, areas on the surface of muscle cells which link them together. The desmosomes are composed of several proteins, and many of those proteins can have harmful mutations.

ARVC can also develop in intense endurance athletes in the absence of desmosomal abnormalities. Exercise-induced ARVC is possibly a result of excessive right ventricular wall stress during high intensity exercise. [2] [3]

The disease is a type of non-ischemic cardiomyopathy that primarily involves the right ventricle, though cases of exclusive left ventricular disease have been reported. It is characterized by hypokinetic areas involving the free wall of the ventricle, with fibrofatty replacement of the myocardium, with associated arrhythmias often originating in the right ventricle. The nomenclature ARVD is currently thought to be inappropriate and misleading as ACM does not involve dysplasia of the ventricular wall. Cases of ACM originating from the left ventricle led to the abandonment of the name ARVC.

ACM can be found in association with diffuse palmoplantar keratoderma, and woolly hair, in an autosomal recessive condition called Naxos disease, because this genetic abnormality can also affect the integrity of the superficial layers of the skin most exposed to pressure stress. [4] : 513  [5]

ACM is an important cause of ventricular arrhythmias in children and young adults. It is seen predominantly in males, and 30–50% of cases have a familial distribution.

Signs and symptoms

Those affected by arrhythmogenic cardiomyopathy may not have any symptoms at all despite having significant abnormalities in the structure of their hearts. [6] If symptoms do occur, the initial presentation is often due to abnormal heart rhythms (arrhythmias) which in arrhythmogenic cardiomyopathy may take the form of palpitations, or blackouts. [7] Sudden death may be the first presentation of ACM without any preceding symptoms. [6] These symptoms often occur during adolescence and early adulthood, but signs of ACM may rarely be seen in infants.

As ACM progresses, the muscle tissue within the ventricles may dilate and weaken. The right ventricle typically weakens first, leading to fatigue and ankle swelling. In the later stages of the disease in which both ventricles are involved shortness of breath may develop, especially when lying flat. [6]

Causes

Genetics

ACM is usually inherited in an autosomal dominant pattern, with variable expression. Only 30% to 50% of individuals affected by ACM will test positive to one of the known genetic mutations in chromosomal loci associated with the disease. [8] [9] Novel studies showed that mutations (point mutations) in genes encoding for desmosomal proteins (see intercalated disc) are the main causatives for the development of this disease. Recently it has been shown, that mutations in the desmin DES gene could cause ACM. [10] Desmin is an intermediate filament protein, which is linked to the desmosomes. Different DES mutations cause an abnormal aggregation of desmin and associated proteins. [11] The penetrance is 20–35% in general, but significantly higher in Italy. Seven gene loci have been implicated in ACM. It is unclear whether the pathogenesis varies with the different loci involved. Standard genetic screening test are currently tested and evaluated in different state of the art cardiovascular research centres and hospitals. Types include:

Type OMIM GeneLocusReference
ARVD1lpl 107970 TGFB3 14q23-q24 [12]
ARVD2 600996 RYR2 1q42-q43 [13]
ARVD3 602086  ?14q12-q22 [14]
ARVD4 602087  ?2q32.1-q32.3 [15]
ARVD5 604400 TMEM43 3p23 [16] [17]
ARVD6 604401  ?10p14-p12 [18]
ARVD7 609160 DES 10q22.3 [19] [10] [20]
ARVD8 607450 DSP 6p24 [21]
ARVD9 609040 PKP2 12p11 [22]
ARVD10 610193 DSG2 18q12.1-q12 [23] [24] [25]
ARVD11 610476 DSC2 18q12.1 [26] [27] [28]
ARVD12 611528 JUP 17q21 [29] [30]
ILK 11p15.4 [31]
LMNA [32]

Exercise-induced ARVC

In recent years, several studies have found that excessive long-term sports activity can cause exercise-induced arrhythmogenic right ventricular cardiomyopathy (EIARVC). [33] [34] For some athletes ARVC might develop due to high-endurance exercise and it most often develops without an underlying desmosomal abnormalities. This could possibly be a result of excessive right ventricular (RV) wall stress during very high volumes of training, which is known to be causing a disproportionate remodeling of RV. [35] [36]

In a 2003 study, 46 endurance athletes, mostly cyclists, presented with various symptoms suggestive of arrhythmia of RV origin. 59% of participants tested met the criteria for ARVC, and another 30% for possible ARVC. Only 1 athlete of the group had a family history of hereditary ARVC. [33]

Exercise-induced ARVC and athlete's heart have overlapping features. [37]

Pathogenesis

The pathogenesis of ACM is largely unknown. Apoptosis (programmed cell death) appears to play a large role. It was previously thought that only the right ventricle is involved, but recent cohorts have shown many cases of left ventricular disease and biventricular disease. The disease process starts in the subepicardial region and works its way towards the endocardial surface, leading to transmural involvement (possibly accounting for the aneurysmal dilatation of the ventricles). Residual myocardium is confined to the subendocardial region and the trabeculae of the ventricles. These trabeculae may become hypertrophied.

Aneurysmal dilatation is seen in 50% of cases at autopsy. It usually occurs in the diaphragmatic, apical, and infundibular regions (known as the triangle of dysplasia). The left ventricle is involved in 50–67% of individuals. If the left ventricle is involved, it is usually late in the course of disease, and confers a poor prognosis.

There are two pathological patterns seen in ACM, Fatty infiltration and fibro-fatty infiltration.

Fatty infiltration

At first, fatty infiltration, is confined to the right ventricle. This involves a partial or near-complete substitution of myocardium with fatty tissue without wall thinning. It involves predominantly the apical and infundibular regions of the RV. The left ventricle and ventricular septum are usually spared. No inflammatory infiltrates are seen in fatty infiltration. There is evidence of myocyte (myocardial cell) degeneration and death seen in 50% of cases of fatty infiltration.

Fibro-fatty infiltration

The second, fibro-fatty infiltration, involves replacement of myocytes with fibrofatty tissue. A patchy myocarditis is involved in up to 2/3 of cases, with inflammatory infiltrates (mostly T cells) seen on microscopy. Myocardial atrophy is due to injury and apoptosis. This leads to thinning of the RV free wall (to < 3 mm thickness) Myocytes are replaced with fibrofatty tissue. The regions preferentially involved include the RV inflow tract, the RV outflow tract, and the RV apex. However, the LV free wall may be involved in some cases. Involvement of the ventricular septum is rare. The areas involved are prone to aneurysm formation.

The Role of Exercise

Recently, some studies have identified strenuous exercise as a novel risk for accelerated progression of the disease. One retrospective study on 301 patients conclusively demonstrated that the subpopulations participating in strenuous physical activity (professional athletes for example) had an earlier onset of symptoms and earlier mortality compared to other populations. [38]

Ventricular arrhythmias

Monomorphic ventricular tachycardia originating from the right ventricular outflow tract RVOT Tachycardia.png
Monomorphic ventricular tachycardia originating from the right ventricular outflow tract

Ventricular arrhythmias due to ACM typically arise from the diseased right ventricle. The type of arrhythmia ranges from frequent premature ventricular complexes (PVCs) to ventricular tachycardia (VT) to ventricular fibrillation (VF).

While the initiating factor of the ventricular arrhythmias is unclear, it may be due to triggered activity or reentry.

Ventricular arrhythmias are usually exercise-related, suggesting that they are sensitive to catecholamines. The ventricular beats typically have a right axis deviation. Multiple morphologies of ventricular tachycardia may be present in the same individual, suggesting multiple arrhythmogenic foci or pathways.

Right ventricular outflow tract (RVOT) tachycardia is the most common VT seen in individuals with ACM. In this case, the EKG shows a left bundle branch block (LBBB) morphology with an inferior axis.

Diagnosis

The differential diagnosis for the ventricular tachycardia due to ACM include:

In order to make the diagnosis of ACM, a number of clinical tests are employed, including the electrocardiogram (EKG), echocardiography, right ventricular angiography, cardiac MRI, and genetic testing.

Electrocardiogram

90% of individuals with ARVD have some EKG abnormality. The most common EKG abnormality seen in ACM is T wave inversion in leads V1 to V3. However, this is a non-specific finding, and may be considered a normal variant in right bundle branch block (RBBB), women, and children under 12 years old.

RBBB itself is seen frequently in individuals with ACM. This may be due to delayed activation of the right ventricle, rather than any intrinsic abnormality in the right bundle branch.

The epsilon wave (marked by red triangle), seen in ARVD. ARVD-Epsilon wave.png
The epsilon wave (marked by red triangle), seen in ARVD.

The epsilon wave is found in about 50% of those with ACM. This is described as a terminal notch in the QRS complex. It is due to slowed intraventricular conduction. The epsilon wave may be seen on a surface EKG; however, it is more commonly seen on signal averaged EKGs.

Ventricular ectopy seen on a surface EKG in the setting of ACM is typically of left bundle branch block (LBBB) morphology, with a QRS axis of −90 to +110 degrees. The origin of the ectopic beats is usually from one of the three regions of fatty degeneration (the "triangle of dysplasia"): the RV outflow tract, the RV inflow tract, and the RV apex.

Signal averaged ECG (SAECG) is used to detect late potentials and epsilon waves in individuals with ACM.

Echocardiography

Echocardiography may reveal an enlarged, hypokinetic right ventricle with a paper-thin RV free wall. The dilatation of the RV will cause dilatation of the tricuspid valve annulus, with subsequent tricuspid regurgitation. Paradoxical septal motion may also be present.

Magnetic resonance imaging

MRI in a patient affected by ARVC/D (long axis view of the right ventricle): note the transmural diffuse bright signal in the RV free wall on spin echo T1 (a) due to massive myocardial atrophy with fatty replacement (b). Arvd MRI.jpg
MRI in a patient affected by ARVC/D (long axis view of the right ventricle): note the transmural diffuse bright signal in the RV free wall on spin echo T1 (a) due to massive myocardial atrophy with fatty replacement (b).
In vitro MRI and corresponding cross section of the heart in ARVD show RV dilatation with anterior and posterior aneurysms (17-year-old asymptomatic male athlete who died suddenly during a soccer game). Arrhythmogenic right ventricular cardiomyopathy.jpg
In vitro MRI and corresponding cross section of the heart in ARVD show RV dilatation with anterior and posterior aneurysms (17-year-old asymptomatic male athlete who died suddenly during a soccer game).

Fatty infiltration of the RV free wall can be visible on cardiac MRI. Fat has increased intensity in T1-weighted images. However, it may be difficult to differentiate intramyocardial fat and the epicardial fat that is commonly seen adjacent to the normal heart. Also, the sub-tricuspid region may be difficult to distinguish from the atrioventricular sulcus, which is rich in fat.

Cardiac MRI can visualize the extreme thinning and akinesis of the RV free wall. However, the normal RV free wall may be about 3 mm thick, making the test less sensitive.

Angiography

Right ventricular angiography is considered the gold standard for the diagnosis of ACM. Findings consistent with ACM are an akinetic or dyskinetic bulging localized to the infundibular, apical, and subtricuspid regions of the RV. The specificity is 90%; however, the test is observer dependent.

Biopsy

Transvenous biopsy of the right ventricle can be highly specific for ACM, but it has low sensitivity. False positives include other conditions with fatty infiltration of the ventricle, such as long-term excessive alcohol use and Duchenne or Becker muscular dystrophy.

False negatives are common, however, because the disease progresses typically from the epicardium to the endocardium (with the biopsy sample coming from the endocardium), and the segmental nature of the disease. Also, due to the paper-thin right ventricular free wall that is common in this disease process, most biopsy samples are taken from the ventricular septum, which is commonly not involved in the disease process.

A biopsy sample that is consistent with ACM would have > 3% fat, >40% fibrous tissue, and <45% myocytes.

A post mortem histological demonstration of full thickness substitution of the RV myocardium by fatty or fibro-fatty tissue is consistent with ACM.

Genetic testing

ACM is an autosomal dominant trait with reduced penetrance. Approximately 40–50% of ACM patients have a mutation identified in one of several genes encoding components of the desmosome, which can help confirm a diagnosis of ACM. [39] Since ACM is an autosomal dominant trait, children of an ACM patient have a 50% chance of inheriting the disease-causing mutation. Whenever a mutation is identified by genetic testing, family-specific genetic testing can be used to differentiate between relatives who are at-risk for the disease and those who are not. ACM genetic testing is clinically available. [40]

Diagnostic criteria

There is no pathognomonic feature of ACM. The diagnosis of ACM is based on a combination of major and minor criteria. To make a diagnosis of ACM requires either 2 major criteria or 1 major and 2 minor criteria or 4 minor criteria. [41]

Major criteria

Minor criteria

Management

The goal of management of ACM is to decrease the incidence of sudden cardiac death. This raises a clinical dilemma: How to prophylactically treat the asymptomatic patient who was diagnosed during family screening.

A certain subgroup of individuals with ACM are considered at high risk for sudden cardiac death. Associated characteristics include:

Management options include pharmacological, surgical, catheter ablation, and placement of an implantable cardioverter-defibrillator.

Prior to the decision of the treatment option, programmed electrical stimulation in the electrophysiology laboratory may be performed for additional prognostic information. Goals of programmed stimulation include:

Regardless of the management option chosen, the individual is typically advised to undergo lifestyle modification, including avoidance of strenuous exercise, cardiac stimulants (i.e.: caffeine, nicotine, pseudoephedrine) and alcohol.

Regarding physical activity and exercise, ARVC patients, as well as gene carriers of pathogenic ARVC-associated desmosomal mutations, should not participate in competitive sports. These patients should be advised to limit their exercise programmes to leisure-time activities and remain under clinical surveillance. [42]

Medication

Pharmacologic management of ACM involves arrhythmia suppression and prevention of thrombus formation.

Sotalol, a beta blocker and a class III antiarrhythmic agent, is the most effective antiarrhythmic agent in ACM. Other antiarrhythmic agents used include amiodarone and conventional beta blockers (i.e.: metoprolol). If antiarrhythmic agents are used, their efficacy should be guided by series ambulatory Holter monitoring, to show a reduction in arrhythmic events.

While angiotensin converting enzyme inhibitors (ACE Inhibitors) are well known for slowing progression in other cardiomyopathies, they have not been proven to be helpful in ACM.

Individuals with decreased RV ejection fraction with dyskinetic portions of the right ventricle may benefit from long term anticoagulation with warfarin to prevent thrombus formation and subsequent pulmonary embolism.

Catheter ablation

Catheter ablation may be used to treat intractable ventricular tachycardia. It has a 60–90% success rate. [43] Unfortunately, due to the progressive nature of the disease, recurrence is common (60% recurrence rate), with the creation of new arrhythmogenic foci. Indications for catheter ablation include drug-refractory VT and frequent recurrence of VT after ICD placement, causing frequent discharges of the ICD.

Implantable cardioverter-defibrillator

An ICD is the most effective prevention against sudden cardiac death. Due to the prohibitive cost of ICDs, they are not routinely placed in all individuals with ACM.

Indications for ICD placement in the setting of ACM include:

Since ICDs are typically placed via a transvenous approach into the right ventricle, there are complications associated with ICD placement and follow-up.

Due to the extreme thinning of the RV free wall, it is possible to perforate the RV during implantation, potentially causing pericardial tamponade. Because of this, every attempt is made at placing the defibrillator lead on the ventricular septum.

After a successful implantation, the progressive nature of the disease may lead to fibro-fatty replacement of the myocardium at the site of lead placement. This may lead to undersensing of the individual's electrical activity (potentially causing inability to sense VT or VF), and inability to pace the ventricle.

Heart transplant

Heart transplant may be performed in ACM. It may be indicated if the arrhythmias associated with the disease are uncontrollable or if there is severe bi-ventricular heart failure that is not manageable with pharmacological therapy.

Family screening

All first degree family members of the affected individual should be screened for ACM. This is used to establish the pattern of inheritance. Screening should begin during the teenage years unless otherwise indicated. Screening tests include:

Prognosis

There is a long asymptomatic lead-time in individuals with ACM. While this is a genetically transmitted disease, individuals in their teens may not have any characteristics of ACM on screening tests.

Many individuals have symptoms associated with ventricular tachycardia, such as palpitations, light-headedness, or syncope. Others may have symptoms and signs related to right ventricular failure, such as lower extremity edema, or liver congestion with elevated hepatic enzymes.

ACM is a progressive disease. Over time, the right ventricle becomes more involved, leading to right ventricular failure. The right ventricle will fail before there is left ventricular dysfunction. However, by the time the individual has signs of overt right ventricular failure, there will be histological involvement of the left ventricle. Eventually, the left ventricle will also become involved, leading to bi-ventricular failure. Signs and symptoms of left ventricular failure may become evident, including congestive heart failure, atrial fibrillation, and an increased incidence of thromboembolic events.

Epidemiology

The prevalence of ACM is about 1/10,000 in the general population in the United States, although some studies have suggested that it may be as common as 1/1,000. Recently, 1/200 were found to be carriers of mutations that predispose to ACM. [44] Based on these findings and other evidence, it is thought that in most patients, additional factors such as other genes, athletic lifestyle, exposure to certain viruses, etc. may be required for a patient to eventually develop signs and symptoms of ACM. [45] It accounts for up to 17% of all sudden cardiac deaths in the young. In Italy, the prevalence is 40/10,000, making it the most common cause of sudden cardiac death in the young population. [46]

Society and culture

Notable cases

See also

Related Research Articles

<span class="mw-page-title-main">Cardiomyopathy</span> Disease of the heart muscle

Cardiomyopathy is a group of primary diseases of the heart muscle. Early on there may be few or no symptoms. As the disease worsens, shortness of breath, feeling tired, and swelling of the legs may occur, due to the onset of heart failure. An irregular heart beat and fainting may occur. Those affected are at an increased risk of sudden cardiac death.

<span class="mw-page-title-main">Desmosome</span> Cell junction involved in cell-to-cell adhesion

A desmosome, also known as a macula adherens, is a cell structure specialized for cell-to-cell adhesion. A type of junctional complex, they are localized spot-like adhesions randomly arranged on the lateral sides of plasma membranes. Desmosomes are one of the stronger cell-to-cell adhesion types and are found in tissue that experience intense mechanical stress, such as cardiac muscle tissue, bladder tissue, gastrointestinal mucosa, and epithelia.

Hypertrophic cardiomyopathy is a condition in which muscle tissues of the heart become thickened without an obvious cause. The parts of the heart most commonly affected are the interventricular septum and the ventricles. This results in the heart being less able to pump blood effectively and also may cause electrical conduction problems. Specifically, within the bundle branches that conduct impulses through the interventricular septum and into the Purkinje fibers, as these are responsible for the depolarization of contractile cells of both ventricles.

<span class="mw-page-title-main">Dilated cardiomyopathy</span> Condition involving an enlarged, ineffective heart

Dilated cardiomyopathy (DCM) is a condition in which the heart becomes enlarged and cannot pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in chest pain or fainting. Complications can include heart failure, heart valve disease, or an irregular heartbeat.

<span class="mw-page-title-main">Ventricular tachycardia</span> Medical condition of the heart

Ventricular tachycardia is a cardiovascular disorder in which fast heart rate occurs in the ventricles of the heart. Although a few seconds of VT may not result in permanent problems, longer periods are dangerous; and multiple episodes over a short period of time are referred to as an electrical storm. Short periods may occur without symptoms, or present with lightheadedness, palpitations, shortness of breath, chest pain, and decreased level of consciousness. Ventricular tachycardia may lead to coma and persistent vegetative state due to lack of blood and oxygen to the brain. Ventricular tachycardia may result in ventricular fibrillation (VF) and turn into cardiac arrest. This conversion of the VT into VF is called the degeneration of the VT. It is found initially in about 7% of people in cardiac arrest.

<span class="mw-page-title-main">Desmin</span> Mammalian protein found in humans

Desmin is a protein that in humans is encoded by the DES gene. Desmin is a muscle-specific, type III intermediate filament that integrates the sarcolemma, Z disk, and nuclear membrane in sarcomeres and regulates sarcomere architecture.

<span class="mw-page-title-main">Restrictive cardiomyopathy</span> Medical condition

Restrictive cardiomyopathy (RCM) is a form of cardiomyopathy in which the walls of the heart are rigid. Thus the heart is restricted from stretching and filling with blood properly. It is the least common of the three original subtypes of cardiomyopathy: hypertrophic, dilated, and restrictive.

<span class="mw-page-title-main">Desmoglein-2</span> Protein found in humans

Desmoglein-2 is a protein that in humans is encoded by the DSG2 gene. Desmoglein-2 is highly expressed in epithelial cells and cardiomyocytes. Desmoglein-2 is localized to desmosome structures at regions of cell-cell contact and functions to structurally adhere adjacent cells together. In cardiac muscle, these regions are specialized regions known as intercalated discs. Mutations in desmoglein-2 have been associated with arrhythmogenic right ventricular cardiomyopathy and familial dilated cardiomyopathy.

<span class="mw-page-title-main">Desmoplakin</span> Protein found in humans

Desmoplakin is a protein in humans that is encoded by the DSP gene. Desmoplakin is a critical component of desmosome structures in cardiac muscle and epidermal cells, which function to maintain the structural integrity at adjacent cell contacts. In cardiac muscle, desmoplakin is localized to intercalated discs which mechanically couple cardiac cells to function in a coordinated syncytial structure. Mutations in desmoplakin have been shown to play a role in dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, where it may present with acute myocardial injury; striate palmoplantar keratoderma, Carvajal syndrome and paraneoplastic pemphigus.

<span class="mw-page-title-main">Plakoglobin</span> Mammalian protein found in Homo sapiens

Plakoglobin, also known as junction plakoglobin or gamma-catenin, is a protein that in humans is encoded by the JUP gene. Plakoglobin is a member of the catenin protein family and homologous to β-catenin. Plakoglobin is a cytoplasmic component of desmosomes and adherens junctions structures located within intercalated discs of cardiac muscle that function to anchor sarcomeres and join adjacent cells in cardiac muscle. Mutations in plakoglobin are associated with arrhythmogenic right ventricular dysplasia.

<span class="mw-page-title-main">Athletic heart syndrome</span> Medical condition

Athletic heart syndrome (AHS) is a non-pathological condition commonly seen in sports medicine in which the human heart is enlarged, and the resting heart rate is lower than normal.

<span class="mw-page-title-main">Noncompaction cardiomyopathy</span> Congenital disease of heart muscle

Noncompaction cardiomyopathy (NCC) is a rare congenital disease of heart muscle that affects both children and adults. It results from abnormal prenatal development of heart muscle.

<span class="mw-page-title-main">Ryanodine receptor 2</span> Transport protein and coding gene in humans

Ryanodine receptor 2 (RYR2) is one of a class of ryanodine receptors and a protein found primarily in cardiac muscle. In humans, it is encoded by the RYR2 gene. In the process of cardiac calcium-induced calcium release, RYR2 is the major mediator for sarcoplasmic release of stored calcium ions.

<span class="mw-page-title-main">DSC2</span> Protein-coding gene in humans

Desmocollin-2 is a protein that in humans is encoded by the DSC2 gene. Desmocollin-2 is a cadherin-type protein that functions to link adjacent cells together in specialized regions known as desmosomes. Desmocollin-2 is widely expressed, and is the only desmocollin isoform expressed in cardiac muscle, where it localizes to intercalated discs. Mutations in DSC2 have been causally linked to arrhythmogenic right ventricular cardiomyopathy.

<span class="mw-page-title-main">Plakophilin-2</span> Protein-coding gene in the species Homo sapiens

Plakophilin-2 is a protein that in humans is encoded by the PKP2 gene. Plakophilin 2 is expressed in skin and cardiac muscle, where it functions to link cadherins to intermediate filaments in the cytoskeleton. In cardiac muscle, plakophilin-2 is found in desmosome structures located within intercalated discs. Mutations in PKP2 have been shown to be causal in arrhythmogenic right ventricular cardiomyopathy.

Desmocollins are a subfamily of desmosomal cadherins, the transmembrane constituents of desmosomes. They are co-expressed with desmogleins to link adjacent cells by extracellular adhesion. There are seven desmosomal cadherins in humans, three desmocollins and four desmogleins. Desmosomal cadherins allow desmosomes to contribute to the integrity of tissue structure in multicellular living organisms.

Boxer cardiomyopathy is a disease of the myocardium primarily affecting Boxer dogs. It is characterized by the development of ventricular tachyarrhythmias, resulting in syncope and sudden cardiac death. Myocardial failure and congestive heart failure are uncommon manifestations of the disease.

<span class="mw-page-title-main">Arrhythmia</span> Group of medical conditions characterized by irregular heartbeat

Arrhythmias, also known as cardiac arrhythmias, are irregularities in the heartbeat, including when it is too fast or too slow. A resting heart rate that is too fast – above 100 beats per minute in adults – is called tachycardia, and a resting heart rate that is too slow – below 60 beats per minute – is called bradycardia. Some types of arrhythmias have no symptoms. Symptoms, when present, may include palpitations or feeling a pause between heartbeats. In more serious cases, there may be lightheadedness, passing out, shortness of breath, chest pain, or decreased level of consciousness. While most cases of arrhythmia are not serious, some predispose a person to complications such as stroke or heart failure. Others may result in sudden death.

Heart rhythm disturbances have been seen among astronauts. Most of these have been related to cardiovascular disease, but it is not clear whether this was due to pre-existing conditions or effects of space flight. It is hoped that advanced screening for coronary disease has greatly mitigated this risk. Other heart rhythm problems, such as atrial fibrillation, can develop over time, necessitating periodic screening of crewmembers’ heart rhythms. Beyond these terrestrial heart risks, some concern exists that prolonged exposure to microgravity may lead to heart rhythm disturbances. Although this has not been observed to date, further surveillance is warranted.

Frank I. Marcus was an American cardiologist and Emeritus Professor of Medicine at the University of Arizona Health Sciences Center, the author of more than 290 publications in peer-reviewed medical journals and of 90 book chapters. He was considered a world expert on arrhythmogenic right ventricular cardiomyopathy (ARVC) and was a member of the Editorial/Scientific Board of 14 Cardiovascular Journals as well as a reviewer for 26 other medical publications.

References

  1. ↑ Pilichou K, Thiene G, Bauce B, Rigato I, Lazzarini E, Migliore F, et al. (April 2016). "Arrhythmogenic cardiomyopathy". Orphanet Journal of Rare Diseases. 11 (1): 33. doi: 10.1186/s13023-016-0407-1 . PMC   4818879 . PMID   27038780.
  2. ↑ Heidbuchel H, Prior DL, La Gerche A (November 2012). "Ventricular arrhythmias associated with long-term endurance sports: what is the evidence?". British Journal of Sports Medicine. 46 (Suppl 1): i44–i50. doi: 10.1136/bjsports-2012-091162 . PMID   23097479. S2CID   41256939.
  3. ↑ "Exercise-induced arrhythmogenic right ventricular cardiomyopathy: fact or fallacy?". 2011. Retrieved 2022-02-18.
  4. ↑ Freedberg IM, Fitzpatrick TB (2003). Fitzpatrick's Dermatology in General Medicine (6th ed.). McGraw-Hill. ISBN   978-0-07-138076-8.
  5. ↑ James WD, Berger TG, Elston DM, Odom RB (2006). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. ISBN   978-0-7216-2921-6.
  6. 1 2 3 Corrado D, Basso C, Judge DP (September 2017). "Arrhythmogenic Cardiomyopathy". Circulation Research. 121 (7): 784–802. doi:10.1161/CIRCRESAHA.117.309345. PMC   4818879 . PMID   28912183.
  7. ↑ Corrado D, Link MS, Calkins H (January 2017). "Arrhythmogenic Right Ventricular Cardiomyopathy". The New England Journal of Medicine. 376 (1): 61–72. doi:10.1056/NEJMra1509267. PMID   28052233. S2CID   7754633.
  8. ↑ Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorman M, Bhuiyan ZA, et al. (June 2011). "Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study". Circulation. 123 (23): 2690–2700. doi: 10.1161/circulationaha.110.988287 . PMID   21606396.
  9. ↑ Fressart V, Duthoit G, Donal E, Probst V, Deharo JC, Chevalier P, et al. (June 2010). "Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice". Europace. 12 (6): 861–868. doi: 10.1093/europace/euq104 . PMID   20400443.
  10. 1 2 Klauke B, Kossmann S, Gaertner A, Brand K, Stork I, Brodehl A, et al. (December 2010). "De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy". Human Molecular Genetics. 19 (23): 4595–4607. doi: 10.1093/hmg/ddq387 . PMID   20829228.
  11. ↑ Brodehl A, Hedde PN, Dieding M, Fatima A, Walhorn V, Gayda S, et al. (May 2012). "Dual color photoactivation localization microscopy of cardiomyopathy-associated desmin mutants". The Journal of Biological Chemistry. 287 (19): 16047–16057. doi: 10.1074/jbc.M111.313841 . PMC   3346104 . PMID   22403400.
  12. ↑ Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, et al. (February 2005). "Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1". Cardiovascular Research. 65 (2): 366–373. doi: 10.1016/j.cardiores.2004.10.005 . PMID   15639475.
  13. ↑ Milting H, Lukas N, Klauke B, Körfer R, Perrot A, Osterziel KJ, et al. (August 2006). "Composite polymorphisms in the ryanodine receptor 2 gene associated with arrhythmogenic right ventricular cardiomyopathy". Cardiovascular Research. 71 (3): 496–505. doi: 10.1016/j.cardiores.2006.04.004 . PMID   16769042.
  14. ↑ Severini GM, Krajinovic M, Pinamonti B, Sinagra G, Fioretti P, Brunazzi MC, et al. (January 1996). "A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14". Genomics. 31 (2): 193–200. doi:10.1006/geno.1996.0031. hdl:1765/58364. PMID   8824801.
  15. ↑ Rampazzo A, Nava A, Miorin M, Fonderico P, Pope B, Tiso N, et al. (October 1997). "ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm". Genomics. 45 (2): 259–263. doi:10.1006/geno.1997.4927. hdl:11577/2461314. PMID   9344647.
  16. ↑ Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, et al. (April 2008). "Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene". American Journal of Human Genetics. 82 (4): 809–821. doi:10.1016/j.ajhg.2008.01.010. PMC   2427209 . PMID   18313022.
  17. ↑ Christensen AH, Andersen CB, Tybjaerg-Hansen A, Haunso S, Svendsen JH (September 2011). "Mutation analysis and evaluation of the cardiac localization of TMEM43 in arrhythmogenic right ventricular cardiomyopathy". Clinical Genetics. 80 (3): 256–264. doi:10.1111/j.1399-0004.2011.01623.x. PMID   21214875. S2CID   5617616.
  18. ↑ Li D, Ahmad F, Gardner MJ, Weilbaecher D, Hill R, Karibe A, et al. (January 2000). "The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14". American Journal of Human Genetics. 66 (1): 148–156. doi:10.1086/302713. PMC   1288320 . PMID   10631146.
  19. ↑ Protonotarios A, Brodehl A, Asimaki A, Jager J, Quinn E, Stanasiuk C, et al. (June 2021). "The Novel Desmin Variant p.Leu115Ile Is Associated With a Unique Form of Biventricular Arrhythmogenic Cardiomyopathy". The Canadian Journal of Cardiology. 37 (6): 857–866. doi:10.1016/j.cjca.2020.11.017. PMID   33290826. S2CID   228078648.
  20. ↑ Bermúdez-Jiménez FJ, Carriel V, Brodehl A, Alaminos M, Campos A, Schirmer I, et al. (April 2018). "Novel Desmin Mutation p.Glu401Asp Impairs Filament Formation, Disrupts Cell Membrane Integrity, and Causes Severe Arrhythmogenic Left Ventricular Cardiomyopathy/Dysplasia". Circulation. 137 (15): 1595–1610. doi: 10.1161/CIRCULATIONAHA.117.028719 . hdl: 10481/89514 . PMID   29212896.
  21. ↑ Bauce B, Basso C, Rampazzo A, Beffagna G, Daliento L, Frigo G, et al. (August 2005). "Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations". European Heart Journal. 26 (16): 1666–1675. doi: 10.1093/eurheartj/ehi341 . PMID   15941723.
  22. ↑ Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, et al. (November 2004). "Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy". Nature Genetics. 36 (11): 1162–1164. doi: 10.1038/ng1461 . PMID   15489853.
  23. ↑ Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, et al. (March 2006). "Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy". Circulation. 113 (9): 1171–1179. doi: 10.1161/CIRCULATIONAHA.105.583674 . PMID   16505173.
  24. ↑ Awad MM, Dalal D, Cho E, Amat-Alarcon N, James C, Tichnell C, et al. (July 2006). "DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy". American Journal of Human Genetics. 79 (1): 136–142. doi:10.1086/504393. PMC   1474134 . PMID   16773573.
  25. ↑ Brodehl A, Meshkov A, Myasnikov R, Kiseleva A, Kulikova O, Klauke B, et al. (April 2021). "Hemi- and Homozygous Loss-of-Function Mutations in DSG2 (Desmoglein-2) Cause Recessive Arrhythmogenic Cardiomyopathy with an Early Onset". International Journal of Molecular Sciences. 22 (7): 3786. doi: 10.3390/ijms22073786 . PMC   8038858 . PMID   33917638.
  26. ↑ Brodehl A, Weiss J, Debus JD, Stanasiuk C, Klauke B, Deutsch MA, et al. (April 2020). "A homozygous DSC2 deletion associated with arrhythmogenic cardiomyopathy is caused by uniparental isodisomy". Journal of Molecular and Cellular Cardiology. 141: 17–29. doi: 10.1016/j.yjmcc.2020.03.006 . PMID   32201174.
  27. ↑ Heuser A, Plovie ER, Ellinor PT, Grossmann KS, Shin JT, Wichter T, et al. (December 2006). "Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy". American Journal of Human Genetics. 79 (6): 1081–1088. doi:10.1086/509044. PMC   1698714 . PMID   17186466.
  28. ↑ Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S, et al. (November 2006). "Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2". American Journal of Human Genetics. 79 (5): 978–984. doi:10.1086/509122. PMC   1698574 . PMID   17033975.
  29. ↑ Antoniades L, Tsatsopoulou A, Anastasakis A, Syrris P, Asimaki A, Panagiotakos D, et al. (September 2006). "Arrhythmogenic right ventricular cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin (Naxos disease) in families from Greece and Cyprus: genotype-phenotype relations, diagnostic features and prognosis". European Heart Journal. 27 (18): 2208–2216. doi:10.1093/eurheartj/ehl184. PMID   16893920.
  30. ↑ Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ (November 2007). "A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy". American Journal of Human Genetics. 81 (5): 964–973. doi:10.1086/521633. PMC   2265660 . PMID   17924338.
  31. ↑ Brodehl A, Rezazadeh S, Williams T, Munsie NM, Liedtke D, Oh T, et al. (June 2019). "Mutations in ILK, encoding integrin-linked kinase, are associated with arrhythmogenic cardiomyopathy". Translational Research. 208: 15–29. doi:10.1016/j.trsl.2019.02.004. PMC   7412573 . PMID   30802431.
  32. ↑ Forleo C, Carmosino M, Resta N, Rampazzo A, Valecce R, Sorrentino S, et al. (2015). "Clinical and functional characterization of a novel mutation in lamin a/c gene in a multigenerational family with arrhythmogenic cardiac laminopathy". PLOS ONE. 10 (4): e0121723. Bibcode:2015PLoSO..1021723F. doi: 10.1371/journal.pone.0121723 . PMC   4383583 . PMID   25837155.
  33. 1 2 La Gerche A (January 2021). "Exercise-Induced Arrhythmogenic (Right Ventricular) Cardiomyopathy Is Real…if you Consider it". JACC. Cardiovascular Imaging. 14 (1): 159–161. doi: 10.1016/j.jcmg.2020.09.014 . PMID   33221208.
  34. ↑ Prior D, La Gerche A (April 2020). "Exercise and Arrhythmogenic Right Ventricular Cardiomyopathy". Heart, Lung & Circulation. 29 (4): 547–555. doi:10.1016/j.hlc.2019.12.007. PMID   31964580.
  35. ↑ Heidbüchel H, La Gerche A (June 2012). "The right heart in athletes. Evidence for exercise-induced arrhythmogenic right ventricular cardiomyopathy". Herzschrittmachertherapie & Elektrophysiologie. 23 (2): 82–86. doi:10.1007/s00399-012-0180-3. PMID   22782727. S2CID   192598349.
  36. ↑ La Gerche A, Heidbüchel H, Burns AT, Mooney DJ, Taylor AJ, Pfluger HB, et al. (June 2011). "Disproportionate exercise load and remodeling of the athlete's right ventricle". Medicine and Science in Sports and Exercise. 43 (6): 974–981. doi: 10.1249/MSS.0b013e31820607a3 . PMID   21085033.
  37. ↑ Darden D, Scheinman MM, Hoffmayer KS (September 2022). "Exercise-induced arrhythmogenic right ventricular cardiomyopathy: Reverse remodeling with detraining". HeartRhythm Case Reports. 8 (9): 599–603. doi:10.1016/j.hrcr.2022.06.003. PMC   9485656 . PMID   36147714. S2CID   249838976.
  38. ↑ Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al. (December 2016). "Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk". Journal of the American College of Cardiology. 68 (23): 2540–2550. doi: 10.1016/j.jacc.2016.09.951 . PMID   27931611.
  39. ↑ Sen-Chowdhry S, Syrris P, McKenna WJ (November 2007). "Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy". Journal of the American College of Cardiology. 50 (19): 1813–1821. doi:10.1016/j.jacc.2007.08.008. PMID   17980246.
  40. ↑ McNally E, MacLeod H, Dellefave-Castillo L (11 May 2023). "Arrhythmogenic Right Ventricular Cardiomyopathy Overview". In Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LH, Gripp KW, Amemiya A (eds.). GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle. PMID   20301310.
  41. ↑ Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. (April 2010). "Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria". Circulation. 121 (13): 1533–1541. doi:10.1161/CIRCULATIONAHA.108.840827. PMC   2860804 . PMID   20172911.
  42. ↑ Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al. (January 2019). "Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC)". European Heart Journal. 40 (1): 19–33. doi: 10.1093/eurheartj/ehy730 . hdl: 2158/1180375 . PMID   30561613.
  43. ↑ Fontaine G, Tonet J, Gallais Y, Lascault G, Hidden-Lucet F, Aouate P, et al. (November 2000). "Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular dysplasia: a 16-year experience". Current Cardiology Reports. 2 (6): 498–506. doi:10.1007/s11886-000-0034-1. PMID   11203287. S2CID   31406061.
  44. ↑ Lahtinen AM, Lehtonen E, Marjamaa A, Kaartinen M, Heliö T, Porthan K, et al. (August 2011). "Population-prevalent desmosomal mutations predisposing to arrhythmogenic right ventricular cardiomyopathy". Heart Rhythm. 8 (8): 1214–1221. doi:10.1016/j.hrthm.2011.03.015. PMID   21397041.
  45. ↑ Jain R. Athletic status and arrhythmogenic right ventricular dysplasia/cardiomyopathy: From physiological observations to pathological explanation. Hypothesis 2010, 8(1): e2. – See more at: http://www.hypothesisjournal.com/?p=844#sthash.aB859Jm2.dpuf
  46. ↑ Corrado D, Fontaine G, Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Need for an International Registry. Circulation. 2000; 101: e101-e106
  47. ↑ Jardy A. "Crew midfielder Kirk Urso, 22, dies after being rushed to hospital from bar". The Columbus Dispatch. The Dispatch Printing Company. Archived from the original on 17 October 2012. Retrieved 21 September 2012.
  48. ↑ Jardy A. "Coroner: Crew's Urso died of a preexisting heart condition". The Columbus Dispatch. The Dispatch Printing Company. Archived from the original on 24 September 2012. Retrieved 21 September 2012.
  49. ↑ "Sevilla star suffers heart attack". BBC Sport. 2007-08-25. Retrieved 2007-08-25.
  50. ↑ "Sevilla star dies after collapse - CNN.com". edition.cnn.com.
  51. ↑ "Cause of Death". Cardiac Inherited Disease Group. Archived from the original on 2006-08-18. Retrieved 2006-10-31.
  52. ↑ "Shock at star player's death". icBirmingham.co.uk. 11 September 2006. Retrieved 2007-11-26.
  53. ↑ Suzanne Crough died of rare heart ailment, coroner says, msn.com; accessed October 27, 2015.
  54. ↑ "James Taylor: England & Nottinghamshire batsman forced to retire". BBC Sport. 2016-04-12. Retrieved 2016-05-15.
  55. ↑ The life and career of Jordan Boyd | NHL Home Team Heroes, 13 October 2019, retrieved 2019-10-14
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.